Q4 2025 · 13F-HR
Foresite Capital Management V, LLCholdings as filed
Filed 2026-02-17 · accession 0001104659-26-015410
$164.4M
Reported value
7
Positions
2025-12-31
Period end
The Brief · Foresite Capital Management V, LLC · Q4 2025
AI · grounded in 13F
Foresite Capital Management V, LLC established a new position in Natera, Inc. NTRA valued at $15.4M. This addition represents the fund's only change to its portfolio this period. The fund now manages 7 positions with total assets under management of $164.4M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 022307102 | ALMS | ALUMIS INC. | $56.4M | 34.3% | 5,779,348 | Common | SOLE |
| 156944100 | CGON | CG Oncology, Inc. | $41.7M | 25.4% | 1,004,050 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $23.7M | 14.4% | 299,069 | Common | SOLE |
| 632307104 | NTRA | Natera, Inc. | $15.4M | 9.39% | 67,356 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $14.7M | 8.93% | 477,078 | Common | SOLE |
| 433000106 | HIMS | Hims & Hers Health, Inc. | $8.9M | 5.39% | 273,151 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $3.6M | 2.17% | 86,291 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.